Syros to Present at JMP Securities Life Sciences Conference

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 15 at 9:30 a.m. ET, held at The Lotte New York Palace, NY. Attendees can join via a live webcast on Syros's website, with an archived replay available for 30 days. Syros focuses on developing medicines that control gene expression for diseases like myelodysplastic syndrome and leukemia, with a clinical pipeline that includes innovative treatments such as tamibarotene and SY-2101.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows:

JMP Securities Life Sciences Conference
Date: Wednesday, June 15
Time: 9:30 a.m. ET
Location: The Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the fireside chat will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005098/en/

Media:

Courtney Solberg

Syros Pharmaceuticals

917-698-9253

csolberg@syros.com



Investor:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

What is the date of Syros Pharmaceuticals' participation at the JMP Securities Life Sciences Conference?

Syros Pharmaceuticals will participate on June 15.

What time will the fireside chat with Nancy Simonian at the JMP Securities Life Sciences Conference take place?

The fireside chat will take place at 9:30 a.m. ET.

Where is the JMP Securities Life Sciences Conference being held?

The conference will be held at The Lotte New York Palace, 455 Madison Avenue, New York, NY.

How can I watch the fireside chat featuring Syros Pharmaceuticals CEO?

You can watch the live webcast on the Investors & Media section of Syros's website.

What does Syros Pharmaceuticals focus on in its research and development?

Syros Pharmaceuticals focuses on medicines that control gene expression, particularly for diseases like myelodysplastic syndrome and acute myeloid leukemia.